TY - JOUR
T1 - Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021–2022
AU - CoVaSC Investigators
AU - Yoon, Dongwon
AU - Jung, Kyungyeon
AU - Kim, Ju Hwan
AU - Ko, Hwa Yeon
AU - Yoon, Byeol A.
AU - Shin, Ju Young
N1 - Publisher Copyright:
© 2024 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2024/11
Y1 - 2024/11
N2 - We conducted a self-controlled case series study to investigate the association between COVID-19 vaccination and facial palsy (FP) in South Korea. We used a large immunization registry linked with the national health information database. We included 44,564,345 patients >18 years of age who received >1 dose of COVID-19 vaccine (BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, or Ad.26.COV2.S) and had an FP diagnosis and corticosteroid prescription within 240 days postvaccination. We compared FP incidence in a risk window (days 1–28) with a control window (the remainder of the 240-day observation period, excluding any risk windows). We found 5,211 patients experienced FP within the risk window and 10,531 experienced FP within the control window. FP risk increased within 28 days postvaccination, primarily after first and second doses and was observed for both mRNA and viral vaccines. Clinicians should carefully assess the FP risk-benefit profile associated with the COVID-19 vaccines and monitor neurologic signs after vaccination.
AB - We conducted a self-controlled case series study to investigate the association between COVID-19 vaccination and facial palsy (FP) in South Korea. We used a large immunization registry linked with the national health information database. We included 44,564,345 patients >18 years of age who received >1 dose of COVID-19 vaccine (BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, or Ad.26.COV2.S) and had an FP diagnosis and corticosteroid prescription within 240 days postvaccination. We compared FP incidence in a risk window (days 1–28) with a control window (the remainder of the 240-day observation period, excluding any risk windows). We found 5,211 patients experienced FP within the risk window and 10,531 experienced FP within the control window. FP risk increased within 28 days postvaccination, primarily after first and second doses and was observed for both mRNA and viral vaccines. Clinicians should carefully assess the FP risk-benefit profile associated with the COVID-19 vaccines and monitor neurologic signs after vaccination.
UR - https://www.scopus.com/pages/publications/85207601221
U2 - 10.3201/eid3011.240610
DO - 10.3201/eid3011.240610
M3 - Article
C2 - 39378869
AN - SCOPUS:85207601221
SN - 1080-6040
VL - 30
SP - 2313
EP - 2322
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 11
ER -
